Myconostica CE marks Aspergillus assay
This article was originally published in Clinica
Executive Summary
UK diagnostics firm Myconostica has CE marked its MycAssay Aspergillus test for sale in Europe. The diagnostic uses real-time PCR to identify the genus of fungus, one of the most common causes of fungal pneumonia. It could improve patient survival, as it can provide results within three hours – when used with Myconostica's fungal DNA extraction system, MycXtra – compared with up to 10 days for conventional methods. Diagnosis of Aspergillus infection and subsequent antifungal treatments within 10 days reduces mortality from 90% to 40%. Pneumonia caused by Aspergillus is the leading cause of infectious death in leukaemia and bone marrow cancer patients, with around 10 million people at risk each year worldwide, the Manchester-based company estimates.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.